Crescent Biopharma Inc (CBIO) Stock Price, Quote & News

Company Profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 460 5595

Website: crescentbiopharma.com

Address:

300 Fifth Avenue, Waltham, United States

STACKD0E Aug. 11 at 6:44 PM

$CBIO 🙃✨️

0 · Reply

BiotechValues Jul. 31 at 1:01 PM

$HOWL remember what happened to $CBIO? Suddenly sold their pre-clinical programs for $60M and stock spiked like 500%. HOWL has their INDUCER TCE programs that are in a very hot space. No doubt someone will come in and buy the platform given the upside potential there. This is what got me interested in HOWL in first place. The language in the PR today suggests "updates" on SA are coming (plural)

0 · Reply

STACKD0E Jul. 30 at 12:00 PM

$CBIO 👁

0 · Reply

ProfProfit Jul. 29 at 5:17 PM

$CBIO what the hell is going on with this POS?

0 · Reply

Aleexandder Jul. 23 at 7:24 PM

$CBIO cooking for the ah

0 · Reply

tradehulk Jul. 22 at 4:37 PM

$CBIO 🚨$CHAI about to trade 50M shares premarket! 💥

0 · Reply

FilingTracker Jul. 20 at 9:31 PM

$CBIO Large insider purchase: https://filingtracker.ai/filing/1253689/0001104659-26-085113

0 · Reply

REIoutdoorsHater Jul. 16 at 2:48 PM

$CBIO That is one hell of a dillution, and they run this up after. It’s a trap! Watch out incoming $9.00

0 · Reply

G101SPM Jul. 15 at 1:50 PM

#DILUTION Crescent Biopharma ($CBIO) prices 8.62M-share public offering at $14.50/share Penguin Solutions ($PENG) prices $650 mln 0.00% convertible notes due 2031 Q32 Bio ($QTTB) prices $200 mln public offering at $18.25/share

0 · Reply

OpenOutcrier Jul. 15 at 1:09 PM

$CBIO (-3.3% pre) Crescent Biopharma prices $125M public offering of shares and warrants https://ooc.bz/l/107887

0 · Reply

Crescent Biopharma Announces Grants of Inducement Awards

2026-07-30T12:00:49.000Z - 15 days ago

Crescent Biopharma reports Q2 EPS (74c), consensus (64c)

Jul 30, 2026, 7:35 AM EDT - 15 days ago

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Jul 30, 2026, 7:30 AM EDT - 15 days ago

Crescent Biopharma Earnings release: Q2 2026

Jul 30, 2026, 7:30 AM EDT - 15 days ago

Crescent Biopharma Quarterly report: Q2 2026

Jul 16, 2026, 4:01 PM EDT - 4 weeks ago

Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

2026-07-15T02:15:08.000Z - 4 weeks ago

Crescent Biopharma 8.095M share Spot Secondary priced at $14.50

Jul 14, 2026, 9:45 PM EDT - 4 weeks ago

Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

2026-07-14T20:25:22.000Z - 4 weeks ago

Crescent Biopharma files ordinary shares offering, no amount given

Jul 14, 2026, 4:01 PM EDT - 4 weeks ago

Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Jul 1, 2026, 8:00 AM EDT - 6 weeks ago

Crescent Biopharma Registration statement: Registration filing

Jun 8, 2026, 8:40 AM EDT - 2 months ago

Crescent Biopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 4:20 PM EDT - 2 months ago

Crescent Biopharma Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 4:15 PM EDT - 2 months ago

Crescent Biopharma to Present at June Investor Conferences

Jun 2, 2026, 9:00 AM EDT - 2 months ago

Crescent Biopharma Transcript: AGM 2026

2026-06-01T10:31:19.000Z - 2 months ago

Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright

May 26, 2026, 11:30 AM EDT - 2 months ago

Crescent Biopharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 21, 2026, 5:30 PM EDT - 3 months ago

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

May 20, 2026, 2:30 PM EDT - 3 months ago

Crescent Biopharma Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 13, 2026, 7:20 PM EDT - 3 months ago

Crescent Biopharma Transcript: Bank of America Global Healthcare Conference 2026

May 6, 2026, 7:30 AM EDT - 3 months ago

Crescent Biopharma to Present at May Investor Conferences

2026-04-29T21:25:20.000Z - 3 months ago

Crescent Biopharma reports Q1 EPS (70c), consensus (79c)

Apr 29, 2026, 4:15 PM EDT - 3 months ago

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Apr 29, 2026, 7:00 AM EDT - 3 months ago

Crescent Biopharma Quarterly report: Q1 2026

Apr 29, 2026, 7:00 AM EDT - 3 months ago

Crescent Biopharma Earnings release: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Crescent Biopharma Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Crescent Biopharma Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Crescent Biopharma Proxy statement: Proxy filing

2026-04-08T20:50:50.000Z - 4 months ago

Crescent Biopharma management to meet with Cantor Fitzgerald

Mar 11, 2026, 8:40 AM EDT - 5 months ago

Crescent Biopharma Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 3:50 PM EST - 5 months ago

Crescent Biopharma Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T11:44:56.000Z - 5 months ago

Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright

2026-02-26T12:49:35.000Z - 6 months ago

Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year

2026-02-26T12:48:53.000Z - 6 months ago

Crescent Biopharma sees cash runway into 2028

Feb 26, 2026, 7:30 AM EST - 6 months ago

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 26, 2026, 7:30 AM EST - 6 months ago

Crescent Biopharma Annual report: Q4 2025

Feb 26, 2026, 7:30 AM EST - 6 months ago

Crescent Biopharma Earnings release: Q4 2025

Feb 23, 2026, 7:30 AM EST - 6 months ago

Crescent Biopharma to Present at March Investor Conferences

2026-02-18T12:36:19.000Z - 6 months ago

Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial

Feb 18, 2026, 7:30 AM EST - 6 months ago

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

Feb 12, 2026, 11:30 AM EST - 6 months ago

Crescent Biopharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:30 AM EST - 6 months ago

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-28T11:36:53.000Z - 7 months ago

Crescent Biopharma initiated with an Overweight at Piper Sandler

2026-01-21T11:35:26.000Z - 7 months ago

Crescent Biopharma initiated with a Buy at Guggenheim

SMMT

2026-01-07T22:15:16.000Z - 7 months ago

Crescent Biopharma files to sell 19.71M shares of common stock for holders

2026-01-05T12:16:19.000Z - 7 months ago

Crescent Biopharma announces regulatory clearance of IND applications

Jan 5, 2026, 7:00 AM EST - 7 months ago

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

2025-12-04T20:35:38.000Z - 9 months ago

Crescent Biopharma price target raised to $32 from $28 at Stifel

Dec 4, 2025, 8:00 AM EST - 9 months ago

Crescent Biopharma Transcript: Partnership

Dec 4, 2025, 8:00 AM EST - 9 months ago

Crescent Biopharma Press release: Partnership

Dec 4, 2025, 8:00 AM EST - 9 months ago

Crescent Biopharma Slides: Partnership

Dec 4, 2025, 6:35 AM EST - 9 months ago

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

Dec 4, 2025, 6:30 AM EST - 9 months ago

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

Nov 19, 2025, 4:30 AM EST - 9 months ago

Crescent Biopharma Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 1:20 PM EST - 9 months ago

Crescent Biopharma Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 8:00 AM EST - 9 months ago

Crescent Biopharma Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:30 AM EST - 10 months ago

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:00 AM EST - 10 months ago

Crescent Biopharma Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Crescent Biopharma Earnings release: Q3 2025

Nov 5, 2025, 7:30 AM EST - 10 months ago

Crescent Biopharma to Present at November Investor Conferences

Nov 4, 2025, 6:00 PM EST - 10 months ago

Crescent Biopharma Slides: Corporate Presentation

Nov 4, 2025, 9:05 AM EST - 10 months ago

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Sep 8, 2025, 5:35 PM EDT - 1 year ago

Crescent Biopharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 1:00 PM EDT - 1 year ago

Crescent Biopharma Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 6:00 PM EDT - 1 year ago

Crescent Biopharma Slides: Corporate Presentation

Aug 28, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma to Present at September Investor Conferences

Jul 31, 2025, 7:34 AM EDT - 1 year ago

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 31, 2025, 7:00 AM EDT - 1 year ago

Crescent Biopharma Earnings release: Q2 2025

Jul 31, 2025, 7:00 AM EDT - 1 year ago

Crescent Biopharma Quarterly report: Q2 2025

Jul 8, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Jul 8, 2025, 7:00 AM EDT - 1 year ago

Crescent Biopharma Slides: Corporate Presentation

Jun 16, 2025, 7:00 AM EDT - 1 year ago

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Jun 5, 2025, 4:01 PM EDT - 1 year ago

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

May 29, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

May 16, 2025, 1:55 PM EDT - 1 year ago

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints David Lubner to Board of Directors

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Mar 5, 2025, 11:20 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

CMRX

Feb 26, 2025, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Nov 12, 2024, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

Oct 29, 2024, 11:47 AM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

PFIE

Oct 29, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Oct 29, 2024, 6:30 AM EDT - 1 year ago

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Jul 25, 2024, 9:00 AM EDT - 2 years ago

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

$GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)$

Jun 4, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

$GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024$

May 29, 2024, 4:01 PM EDT - 2 years ago

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

$GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)$

May 6, 2024, 6:00 AM EDT - 2 years ago

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Apr 25, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

Mar 27, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

Mar 13, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

Feb 26, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

Feb 12, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jan 4, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Dec 10, 2023, 12:00 PM EST - 2 years ago

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Nov 9, 2023, 7:00 AM EST - 3 years ago

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

Nov 3, 2023, 7:00 AM EDT - 3 years ago

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

STACKD0E Aug. 11 at 6:44 PM

$CBIO 🙃✨️

0 · Reply

BiotechValues Jul. 31 at 1:01 PM

0 · Reply

STACKD0E Jul. 30 at 12:00 PM

$CBIO 👁

0 · Reply

ProfProfit Jul. 29 at 5:17 PM

$CBIO what the hell is going on with this POS?

0 · Reply

Aleexandder Jul. 23 at 7:24 PM

$CBIO cooking for the ah

0 · Reply

tradehulk Jul. 22 at 4:37 PM

$CBIO 🚨$CHAI about to trade 50M shares premarket! 💥

0 · Reply

FilingTracker Jul. 20 at 9:31 PM

$CBIO Large insider purchase: https://filingtracker.ai/filing/1253689/0001104659-26-085113

0 · Reply

REIoutdoorsHater Jul. 16 at 2:48 PM

$CBIO That is one hell of a dillution, and they run this up after. It’s a trap! Watch out incoming $9.00

0 · Reply

G101SPM Jul. 15 at 1:50 PM

0 · Reply

OpenOutcrier Jul. 15 at 1:09 PM

$CBIO (-3.3% pre) Crescent Biopharma prices $125M public offering of shares and warrants https://ooc.bz/l/107887

0 · Reply

AlertsAndNews Jul. 15 at 2:35 AM

$CBIO Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants "The ordinary shares are being sold to the public at a price of $14.50 per share and the pre-funded warrants are being sold at a price to the public of $14.499 per pre-funded warrant, which represents the per ordinary share price less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Crescent from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Crescent, are expected to be approximately $125.0 million."

0 · Reply

ajmrtxl Jul. 13 at 3:03 PM

$CBIO 's latest data on SqueezeFinder

0 · Reply

ajmrtxl Jul. 2 at 4:09 PM

$CBIO 's latest data on SqueezeFinder

0 · Reply

G101SPM Jul. 2 at 12:31 PM

#DILUTION Crescent Biopharma ($CBIO) files for $500 mln mixed securities shelf offering. Eastman Kodak ($KODK) files for 4,426,268 share common stock offering by selling shareholders. QXO, Inc ($QXO) files for 19,352 share common stock offering, relates to TopBuild acquisition. Anteris Technologies Global Corp. ($AVR) files for 5,385,000 share common stock offering, relates to warrants.

1 · Reply

Merlintrader Jun. 25 at 3:07 PM

$PALI Russell 2026 Biotech Watchlist: $CNTX $IMMX $CBIO and the Small-Cap Health Care Additions to Watch https://www.merlintrader.com/russell-2026-biotech-watchlist/

0 · Reply

ProfProfit Jun. 23 at 8:06 PM

$CBIO 🤦‍♂️

0 · Reply

outlawinvestor1 Jun. 19 at 9:59 PM

$APGE 💥🥳 $SYRE $ORKA $JBIO $CBIO https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-nears-11-billion-deal-apogee-therapeutics-ft-reports-2026-06-19/

0 · Reply

MorenitaScorp Jun. 8 at 1:58 AM

$CBIO ⌚️

0 · Reply

focafoca99 Jun. 3 at 1:26 PM

$CBIO recorded its annual meeting voting results, electing two Class II directors and approving key shareholder proposals.

0 · Reply

focafoca99 May. 22 at 12:14 AM

$CBIO previewed its ASCEND trial poster for the ASCO 2026 meeting.

0 · Reply

outlawinvestor1 May. 16 at 10:04 AM

updated paragon family of extended life biologics. https://www.paragontherapeutics.com/ $APGE $SYRE $ORKA $JBIO $CBIO

1 · Reply

ProfProfit May. 15 at 12:07 AM

$CBIO why the f did I not buy more at $17 a few days ago??? 🤬

0 · Reply

Market Cap	610.28M
Revenue (ttm)	10.84M
Net Income (ttm)	-153.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,420.11%
Debt to Equity Ratio	0.00

Volume	134,676
Avg Vol	343,382
Day's Range	N/A - N/A
Shares Out	37.14M
Stochastic %K	71%
Beta	1.23
Analysts	Strong Sell
Price Target	$31.33